Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Conmed (CNMD) Shares Repurchased (2026)

Conmed filings provide 6 years of Shares Repurchased readings, the most recent being $37.0 million for Q1 2026.

On a quarterly basis, Shares Repurchased changed N/A to $37.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $37.0 million, a N/A change, with the full-year FY2014 number at $16.9 million, down 66.65% from a year prior.
Shares Repurchased hit $37.0 million in Q1 2026 for Conmed, up from $16.9 million in the prior quarter.
In the past five years, Shares Repurchased ranged from a high of $37.0 million in Q1 2026 to a low of $37.0 million in Q1 2026.